At BeOne Medicines we are relentlessly innovating to accelerate the development and delivery of transformative medicines for cancer to reach more people around the world. From clinical trial enrollment to each stage of the treatment journey, we are building the infrastructure, partnerships, and programs to deliver innovative cancer therapies faster, reliably, and at scale.
With three approved medicines across global markets and more than 30 investigational medicines in development, we are how the world fights cancer.
Founders John V. Oyler and Xiaodong Wang launch a global company with a bold mission: to transform cancer treatment through innovation—making breakthrough medicines not only effective, but also accessible for patients around the world.
Access to innovative cancer therapies starts with global research. A new era of cancer research begins: the Company opens its first R&D center, zeroing in on PARP and RAF pathways.
Discovery programs targeting PD-1 and BTK begin. Out of more than 500 compounds, one molecule stands out—BGB-3111, a BTK inhibitor, becomes the 3,111th compound synthesized in just two years. It marks the start of a future breakthrough.
The Company’s experimental compounds—lifirafenib (RAF), pamiparib (PARP), and zanubrutinib (BTK)—enter clinical development in Australia.
The Company expands its U.S. roots to Massachusetts.
The Company debuts on the Nasdaq, fueling the next stage of growth and innovation in oncology.
A new European office opens in Switzerland – positioning the Company at the heart of a key hub of the global pharmaceutical and biotech ecosystem.
Celgene licensed global (ex-Asia) rights to the Company’s anti-PD-1 antibody tislelizumab.
The Company is listed on the Hong Kong Stock Exchange (HKEX) with a stock code of 06160, raising over $900 million.
BRUKINSA® (zanubrutinib) is approved by the U.S. FDA, becoming the Company’s first approved medicine—just seven years after discovery.
Amgen and the Company entered into a strategic collaboration with a $2.7 billion equity investment from Amgen.
This transition marks the beginning of an important strategic advantage: our fully integrated, in-house model connecting research, translational science, and clinical execution.
The Company surpasses 5,000 global employees.
Listed on the Shanghai Stock Exchange (SSE) STAR Market (Science and Technology Innovation Board of Shanghai Stock Exchange) with a stock code of 688235 on December 15, 2021. The listing made the Company the first biotech in the world to be listed simultaneously on Nasdaq, HKEX, and the Shanghai STAR Market.
The Company opens the Guangzhou Bioisland Innovation Center, a cutting-edge research hub exploring novel cancer pathways to address unmet needs worldwide.
Officially broke ground on its flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, New Jersey. This facility is central to our investment in a globally connected manufacturing network that can support oncology medicines from clinical development through commercialization.
Company surpasses $1 billion in revenue, a testament to growing global influence.
Alpine Phase 3 trial results show our BTK inhibitor demonstrated superior progression-free survival in relapsed or refractory CLL compared to ibrutinib-a major leap forward in treatment outcomes.
TEVIMBRA® gains European approval; global rights regained from Novartis.
In partnership with The Max Foundation and the BeOne Care Foundation, the Company begins delivering medicine at no cost to patients with chronic lymphocytic leukemia across low- and middle-income countries.
Achieved 10,000 volunteer hours worldwide
TEVIMBRA® receives FDA approval, becoming the cornerstone of the Company’s solid tumor portfolio.
One million patients worldwide have now been treated with the Company’s medicines.
Its expanding production capabilities are designed to ensure people living with cancer in the U.S. and globally have reliable, uninterrupted access to our therapies.
Changes stock ticker to ONC reinforcing global focus and commitment to oncology.
These are the results of our collaboration with health systems and stakeholders around the world to shorten timelines and work towards fast and broad access.
Announced name change to BeOne Medicines and redomiciliation to Basel, Switzerland.
The Company renews its partnership with the BeOne Care Foundation and The Max Foundation, building on access provided to more than 300 patients with CLL and planning to support approximately 1,000 patients through 2028.